The Latest Cardiac and Vascular News
Acquisition of external cardiac monitoring technologies and services provider to expand rhythm management diagnostics portfolio and capabilities MARLBOROUGH, Mass., Jan. 21, 2021 /PRNewswire/ — Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Preventice Solutions, Inc., a privately-held company which offers a full portfolio of mobile cardiac […]
David D. Cox, PhD, MBA, seasoned regulatory professional, tapped to lead CytoSorbents global regulatory initiatives and U.S. FDA approval of CytoSorb MONMOUTH JUNCTION, N.J., Jan. 21, 2021 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients around the […]
Scientific Advisory Board Expanded with Additions of Global Medical Pioneers and Distinguished Thought Leaders HINGHAM, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT) continues to enhance its thought leadership capabilities with the addition of several new Scientific Advisory Board (SAB) members: Stephen B. Solomon, MD, a […]
BASKING RIDGE, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that it has entered into securities purchase agreements with certain institutional and accredited investors to raise […]
– Enhances penetration into the large and growing interventional cardiology and electrophysiology markets – Offers products with demonstrated and differentiated clinical benefits – Expected to be accretive to revenue growth, gross margins and adjusted gross margins while providing attractive financial returns – Purchase price of up to $510 million cash […]
Proceeds Support Advancement of VERVE-101 toward Clinical Initiation in 2022 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Verve Therapeutics, a biotech company pioneering gene editing medicines to treat cardiovascular disease, today announced the successful completion of a $94 million Series B financing, led by Wellington Management Company and co-led by Casdin Capital, existing investors. New […]
National Institutes of Health grant will support Cardialen’s development of its implantable, low-energy therapy designed to treat atrial fibrillation, a cardiac arrhythmia associated with debilitating shortness of breath, fatigue, pain, and an increased risk of stroke. MINNEAPOLIS–(BUSINESS WIRE)–Cardialen, Inc., has been awarded a $2.8 million National Institutes of Health (NIH) […]
Hillrom Advances Digital Health Offering With Expansion Into Attractive Ambulatory Cardiac Monitoring Segment CHICAGO, Jan. 19, 2021 /PRNewswire/ — Hillrom (NYSE: HRC) today announced it has reached a definitive agreement to acquire Bardy Diagnostics, Inc. (BardyDx), an innovator in digital health and a leading provider of ambulatory cardiac monitoring technologies. Under the terms of […]
PFÄFFIKON, Switzerland, Jan. 19, 2021 /PRNewswire/ — DiNAQOR, a gene therapy platform company, today announced that it has acquired EHT Technologies GmbH, a Germany-based engineered heart tissue (EHT) technology platform company. Financial terms of the transaction were not disclosed. EHT Technologies was founded in 2015 based upon research on human induced pluripotent stem cells (hiPSC) at […]
Appointments Include: Chair, Clay Johnston, M.D., Ph.D. as well as Members Greg Albers, M.D. and Brett Cucchiara, M.D. AUSTIN, Texas, Jan. 19, 2021 (GLOBE NEWSWIRE) — XBiotech Inc. (NASDAQ: XBIT) announced today the first meeting of its Cerebrovascular Medical Advisory Board (CMAB). The CMAB is comprised of key opinion leaders […]
